Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice.

Journal of Psychopharmacology July 2022 Lauri Elsilä, Juliana Harkki, Emma Enberg et al.

Psychedelics, like lysergic acid diethylamide (LSD), are again being studied as potential therapies for many neuropsychiatric disorders, including addictions. At the same time, the acute effects of psychedelics on rewarding behaviours have been scarcely studied. The current study aimed to clarify if LSD decreases binge-like ethanol drinking in mice, and whether the observed acute effects on...

MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial

Journal of Psychopharmacology June 21, 2022 Terence H. W. Ching, Monnica T. Williams, Julie B. Wang et al. 29 citations

Background: Limited ethnoracial diversity in previous ±3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) trials for posttraumatic stress disorder (PTSD) has prompted questions concerning whether Black, Indigenous, and People of Color (BIPOC) also benefit from this treatment. Methods: Secondary analysis was conducted using a modified intent-to-treat sample pooled from two Phase 2...

β-carboline-independent antidepressant-like effect of the standardized extract of the barks of Mimosa tenuiflora (Willd) Poir. occurs via 5-HT2A/2C receptors in mice

Journal of Psychopharmacology June 20, 2022 Luiz Antonio Miranda de Souza Duarte Filho, Isabela Araújo E Amariz, Rodolfo Hideki Vicente Nishimura et al. 12 citations

Background: Depression is a psychiatric disorder with limited therapy options. Psychedelics are new antidepressant candidates, being the ayahuasca one of the most promising ones. A synergistic combination of N,N-dimethyltryptamine (DMT) and β-carbolines allows ayahuasca antidepressant properties. Another psychedelic and DMT-containing beverage is the jurema wine used religiously by indigenous...

DOI: 10.1177/02698811221104050 (opens in new tab) Antidepressant Traditional medicine Pharmacology Receptor

Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)

Journal of Psychopharmacology June 7, 2022 Emma I Kopra, Jason Ferris, James Rucker et al. 42 citations

Background: Recreational lysergic acid diethylamide (LSD) use is growing in popularity amid increasing research interest on psychedelics and their possible therapeutic potential yet; the potent psychotropic effects of LSD may result in adverse reactions and behaviour. Aims: This study aimed to investigate the 12-month incidence and nature of LSD-related adverse experiences resulting in...

Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology

Journal of Psychopharmacology May 30, 2022 Rebecca Smausz, Joanna C. Neill, John Gigg 60 citations

Psilocybin is a naturally occurring psychedelic compound with profound perception-, emotion- and cognition-altering properties and great potential for treating brain disorders. However, the neural mechanisms mediating its effects require in-depth investigation as there is still much to learn about how psychedelic drugs produce their profound and long-lasting effects. In this review, we outline...

Postpartum depression: A role for psychedelics?

Journal of Psychopharmacology May 30, 2022 Chaitra Jairaj, James J Rucker 13 citations

Background: Postpartum depression (PPD) is a major public health concern and has, at its core, a sense of maternal ‘disconnection’ – from the self, the infant, and the support system. While PPD bears similarities with MDD, there is increasing evidence for its distinct nature, especially with the unique aspect of the mother-infant relationship. Current treatment modalities for PPD, largely based...

Individual and combined effects of cannabidiol and Δ 9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain

Journal of Psychopharmacology May 20, 2022 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 21 citations

Background: Cannabidiol (CBD) and Δ 9 -tetrahydrocannabinol (THC) are the two major constituents of cannabis with contrasting mechanisms of action. THC is the major psychoactive, addiction-promoting, and psychotomimetic compound, while CBD may have opposite effects. The brain effects of these drugs alone and in combination are poorly understood. In particular, the striatum is implicated in the...

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms

Journal of Psychopharmacology April 7, 2022 Emma I Kopra, Jason Ferris, Adam Winstock et al. 65 citations

Background: Psilocybin-containing mushrooms are used for recreational, spiritual, self-development and therapeutic purposes. However, physiologically relatively nontoxic, adverse reactions are occasionally reported. Aims: This study investigated the 12-month prevalence and nature of magic mushroom-related adverse reactions resulting in emergency medical treatment seeking in a global sample of...

DOI: 10.1177/02698811221084063 (opens in new tab) Adverse effect Magic telescope Medical emergency Anesthesia +1

A narrative synthesis of research with 5-MeO-DMT.

Journal of Psychopharmacology March 1, 2022 Anna O. Ermakova, Fiona Dunbar, James Rucker et al. 83 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring, short-acting psychedelic tryptamine, produced by a variety of plant and animal species. Plants containing 5-MeO-DMT have been used throughout history for ritual and spiritual purposes. The aim of this article is to review the available literature about 5-MeO-DMT and inform subsequent clinical development. We searched PubMed...

The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects.

Journal of Psychopharmacology March 1, 2022 Malin Vedøy Uthaug, Alan K. Davis, Trevor Forrest Haas et al. 64 citations

Mescaline is a naturally occurring psychoactive phenethylamine found in several cacti and historically used ceremonially by Indigenous and Latin American populations. Broader recognition of its possible therapeutic value in Western science began in the 1950s; however, knowledge of the safety profile of mescaline and the extent of its use remains limited. The primary aim of this study is to...

The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility

Journal of Psychopharmacology March 1, 2022 Max Wolff, Lea J. Mertens, Marie Walter et al. 57 citations

Background: Many benefits and some harms associated with psychedelic use could be attributable to these drugs’ acceptance/avoidance-promoting effects and corresponding changes in psychological flexibility. Underlying psychological mechanisms are insufficiently understood. Aim: The purpose of this study was the validation of a psychological model of acceptance/avoidance-promoting psychedelic...

Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca

Journal of Psychopharmacology March 1, 2022 Gabrielle Agin-Liebes, Richard J. Zeifman, Jason B. Luoma et al. 51 citations

Background: Evidence suggests that psychedelic-assisted therapy carries transdiagnostic efficacy in the treatment of mental health conditions characterized by low mood and the use of avoidance coping strategies. Aims: While preliminary evidence suggests that psychological flexibility and emotion regulation processes play an important role within psychedelic therapy, this prospective study...

Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study

Journal of Psychopharmacology March 1, 2022 Neiloufar Family, Peter S. Hendricks, Luke T. J. Williams et al. 23 citations

Background: Classic psychedelics hold promise as therapeutics for psychiatric disorders, but require scalable intervention protocols. This proof-of-concept study evaluated the safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg lysergic acid diethylamide (LSD) in healthy adults within a novel intervention paradigm. Methods: Up to three participants were...

DOI: 10.1177/02698811211069103 (opens in new tab) Tolerability Pharmacokinetics Intervention counseling Proof of concept +3

Challenges in translational research: MDMA in the laboratory versus therapeutic settings.

Journal of Psychopharmacology March 1, 2022 Harriet de Wit, Anya K. Bershad, Charles S. Grob 11 citations

Despite substantial progress in the use of mind-altering drugs to treat psychiatric disorders, the psychological processes through which these drugs change mood or behavior are poorly understood. Controlled laboratory studies with well-defined psychological constructs are valuable to understand how these drugs manifest their therapeutic benefit. However, there are substantial methodological...

DOI: 10.1177/02698811211015221 (opens in new tab) Full text (opens in new tab) Mental disorders MDMA Trials Psychedelic research Ecstasy research +12

Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study

Journal of Psychopharmacology March 1, 2022 Peter S. Hendricks, Heith Copes, Neiloufar Family et al. 8 citations

Background: Classic psychedelics show promise in the treatment of mental health conditions; however, more scalable intervention protocols are needed to maximize access to these novel therapeutics. In this proof-of-concept study, perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide (LSD) were evaluated among healthy participants ( N =...

DOI: 10.1177/02698811211055855 (opens in new tab) Lysergic acid diethylamide Thematic analysis Intervention counseling Qualitative research +4

Springtime for psychopharmacology

Journal of Psychopharmacology March 1, 2022 Catherine Bird, A. H. Young

As we head into the (Northern Hemisphere) spring, the Journal publishes another set of papers which illustrate the robust health of the science of psychopharmacology. Once again, papers mostly focus on psychedelic drugs and related topics reflecting the zeitgeist (Young, 2022). de Wit et al. (2022) explore translational challenges and opportunities between clinical research and laboratory...

The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder

Journal of Psychopharmacology February 25, 2022 Francis M. Dijkstra, Aurora JAE van de Loo, Smedra Abdulahad et al. 16 citations

Background: Intranasal esketamine demonstrates rapid improvement of depressive symptoms. However, transient adverse effects (dissociation, sedation and dizziness) may occur, which could impact driving performance. Aims: To evaluate the effects of 84 mg intranasal esketamine on driving performance in unipolar major depressive disorder (MDD) or persistent depressive disorder (PDD) patients....

A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults

Journal of Psychopharmacology February 15, 2022 Jessica L Maples-Keller, Seth D. Norrholm, Mark Burton et al. 53 citations

Background: Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention. Aims: This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans. Methods:...

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.

Journal of Psychopharmacology February 2, 2022 Anne K. Schlag, Jacob S. Aday, Iram Salam et al. 319 citations

BACKGROUND: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue among the public and politicians, tainted by previous stigmatisation and perceptions of risk and danger. OBJECTIVE: This narrative review examines the evidence for potential harms of the classic psychedelics by separating...

DOI: 10.1177/02698811211069100 (opens in new tab) Full text (opens in new tab) Psychedelic research Psychedelics study Risk assessment Risk evaluation +4

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Journal of Psychopharmacology February 1, 2022 Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al. 419 citations

Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods: This...

LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking

Journal of Psychopharmacology February 1, 2022 Isabel Wießner, Marcelo Falchi-Carvalho, Lucas Oliveira Maia et al. 43 citations

Background: Controversy surrounds psychedelics and their potential to boost creativity. To date, psychedelic studies lack a uniform conceptualization of creativity and methodologically rigorous designs. Aims: This study aimed at addressing previous issues by examining the effects of lysergic acid diethylamide (LSD) on creativity using multimodal tasks and multidimensional approaches. Methods:...

DOI: 10.1177/02698811211069113 (opens in new tab) Creativity Divergent thinking Originality Cognitive psychology +9

Subchronic PCP effects on DNA methylation and protein expression of NMDA receptor subunit genes in the prefrontal cortex and hippocampus of female rats

Journal of Psychopharmacology February 1, 2022 C. Loureiro, Helene A Fachim, Michael K Harte et al.

Background: N-methyl-d-aspartate receptor (NMDAR) dysfunction is implicated in schizophrenia, and NMDAR antagonists, such as phencyclidine (PCP), can induce behaviours that mimic aspects of the disorder. Aims: We investigated DNA methylation of Grin1, Grin2a and Grin2b promoter region and NR1 and NR2 protein expression in the prefrontal cortex (PFC) and hippocampus of adult female Lister-hooded...

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.

Journal of Psychopharmacology January 5, 2022 Joseph Peill, Katie Trinci, Hannes Kettner et al. 135 citations

Introduction: As their name suggests, 'psychedelic' (mind-revealing) compounds are thought to catalyse processes of psychological insight; however, few satisfactory scales exist to sample this. This study sought to develop a new scale to measure psychological insight after a psychedelic experience: the Psychological Insight Scale (PIS). Methods: The PIS is a six- to seven-item questionnaire...

DOI: 10.1177/02698811211066709 (opens in new tab) Full text (opens in new tab) Psychedelic research Psychological insight Psychometric scale Therapeutic potential

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

Journal of Psychopharmacology 2022 James Rucker, Lindsey Marwood, Riikka-Liisa Johanna Ajantaival et al. 101 citations

Background: Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. Aim: The aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised...

DOI: 10.1177/02698811211064720 (opens in new tab) Psilocybin Placebo Adverse effect Randomized controlled trial +2

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults

Journal of Psychopharmacology 2022 Grant Jones, Matthew K. Nock 60 citations

Background: Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence, there is a critical need for novel tools to treat suicidal ideation and related mental health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic psychedelics may be two such tools. Aims: The aim of this study was to assess...